Fda grants fast track designation to lipocine for lpcn 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis

Salt lake city , dec. 17, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the u.s. food and drug administration ("fda") has granted fast track designation to lpcn 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis. lpcn 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (poc) phase 2 study in patients with decompensated cirrhosis.
LPCN Ratings Summary
LPCN Quant Ranking